KANJINTI
Google image searchProduct monograph
Active ingredient
trastuzumab, 150 MG/VIAL
DIN: 02518244
Dosage form(s): POWDER FOR SOLUTION
Route(s) of administration: INTRAVENOUS
Description: SINGLE-USE VIAL
Schedule: Prescription / Schedule D
Company: AMGEN CANADA INC
Date: 07-OCT-2021
ATC:
- L01 — ANTINEOPLASTIC AGENTS (ATC, ATC/DDD, )
- L01F — MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES (ATC, ATC/DDD)
- L01FD — HER2 (Human Epidermal Growth Factor Receptor 2) inhibitors (ATC, ATC/DDD)
- L01FD01 — TRASTUZUMAB (ATC/DDD)
Reference brand drug: Herceptin, Herzuma, Kanjinti, Ogivri, Ontruzant, Trazimera
